Sidewinder Therapeutics aims
to deliver next-generation bispecific antibody-drug conjugates (ADCs) that expand the therapeutic window for patients with difficult to treat cancers. Built by a dynamic team of serial entrepreneurs, expert scientists and drug developers, we are advancing bispecific ADCs engineered to target receptor co-complexes that are highly expressed on certain solid tumors with enhanced tumor cell specificity and internalization.